WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results